Abstract:Background: Transmission-based precautions against varicella-zoster virus (VZV) in healthcare settings are determined by the extent of rash (localized vs disseminated) and the immune status of the host. At our facility, immunocompetent patients with localized disease are placed in standard precautions whereas patients with disseminated disease and/or immunocompromised status are placed in airborne and contact isolation. The use of molecular diagnostics has increased recently, and patients can have a PCR positive for VZV in cerebral spinal fluid (CSF) without evidence of pneumonia or disseminated rash. These patients are classified as disseminated disease, but it is unlikely that they are spreading VZV via respiratory aerosols in the absence of other symptoms. Infection prevention guidance is limited in this situation, and these patients may be in unneeded isolation, with the potential for adverse patient effects and overutilizing PPE resources. We have described the clinical characteristics of patients with a PCR positive for VZV in CSF, and we evaluated the risk for transmitting VZV via airborne aerosols. Methods: A retrospective, single-center chart review was performed on all patients admitted with a PCR positive for VZV in CSF between July 2017 and November 2021. Chart review was performed to gather data regarding clinical presentation, patient characteristics, and risk factors. Results: In total, 38 patients were identified who had a PCR positive for VZV in CSF; 22 (57.9%) were male and 16 (42.1%) were female. The median age was 47 years (IQR, 38–69). Also, 15 patients (39.5%) were immunocompromised. Moreover, 26 patients (68.4%) had a rash; 19 (50%) had localized rash; and 7 (18.4%) had disseminated rash involving ≥3 dermatomes. However, 12 patients (31.5%) had neither rash nor pneumonia. Furthermore, 5 patients (13.1%) had PCR positive for VZV in CSF and developed rash within the following 2–7 days (2 with disseminated rash). In addition, 6 patients (15.8%) had pneumonia. Of the 6 patients with pneumonia, 4 (10.5%) were immunocompromised and 3 (7.9%) were above 65-year-old. 32 patients (84.2%) were kept in airborne and contact precautions. 1 (2.6%) patient had a documented record of at least 1 dose of Shingrix vaccine. Conclusions: Most patients with a PCR test positive for VZV in the CSF were not immunocompromised and did not have evidence of disseminated rash or pneumonia. The risk of airborne transmission of VZV via small aerosols appears to be low in patients with a PCR test positive for VZV in the CSF without evidence of disseminated rash or pneumonia. Airborne isolation may not be required for many of these patients. Funding: None Disclosures: None

Prevalence and progression of pneumonia in immunocompetent adults with varicella

Viral etiology of life-threatening pediatric pneumonia: A matched case-control study

Varicella Pneumonia in Immunocompetent Adults: Symptomatic and Asymptomatic Cases

Clinical and radiological features of a cluster of immunocompetent adolescents with varicella pneumonia: a descriptive study

Varicella Pneumonia in Otherwise Healthy 31-Year-Old Female Nonsmoker With No Prior Varicella Immunity

Association between emphysema and other pulmonary computed tomography patterns in primary varicella pneumonia: A retrospective cohort study

Varicella pneumonia in a healthy 31-year-old female with no prior varicella immunity and no skin rush: A case report

Disseminated Varicella-Zoster Virus Presenting With Pneumonitis and Diffuse Alveolar Hemorrhage in an Immunocompetent Patient

The Prevalence of Respiratory Pathogens in Adults with Community-Acquired Pneumonia in an Outpatient Cohort.

Characteristics of viral pneumonia in non-HIV immunocompromised and immunocompetent patients: a retrospective cohort study

Progress in Clinical Research of Varicella Vaccines

Chickenpox: presentation and complications in adults

Progress in the treatment and prevention of varicella

Clinical characteristics of 422 inpatients of viral pneumonia in adults

Pneumonia and central nervous system infection caused by reactivation of varicella-zoster virus in a living-donor kidney transplantation patient: case report and review of the literature

Early treatment with acyclovir for varicella pneumonia in otherwise healthy adults: retrospective controlled study and review.

Current status of diagnosis and treatment of viral pneumonia in adults

Zoster on the brain: Clinical characteristics of patients PCR positive for varicella-zoster virus in cerebrospinal fluid and implications for transmission base

Research Progress of Varicella Epidemiological Features and Prevention Strategies

Epidemiology of varicella and effectiveness of varicella vaccine in Hangzhou, China, 2019

Clinical Features of Varicella in Children in 1980-1999